how should the industry respond to challenges
with productivity and efficiency
why should be adopt new technologies
to better understand bio and chem
digital technology
personalisation
highlight challenges to the industry
- drive to increase productivity (reverse EROOMS law)
- patent cliff ( competition with generic drugs once patent expires causing a fall in revenue )
- diseases may challenge funding models (rare diseases or antibiotics)
technology
high throughput
received lots of hype in early 2000s
parallel synthesis
lab automation
screening of compound libraries
some aspects are still used but some have been improved
industry 4.0 principle applications
cyber physical system ( machine computer data,, automation,, digital twins,, digitalisation,, big data)
applied to pharma development and manufacturing (pharma 4.0)
what is pharma 4.0 tho
helps pharmaceutical companies transition to digitisation era
smart manufacturing,, 4th industrial revolution
pharma 4.0 allows creation of smart factories
lots of advanced sensors and robotics
enable better decision making
internet of things + forth industrial revolution
internet of things
plays a crucial role in pharma 4
involving ai and machine learning into production facilities
data analysis and 4th industrial revolution
sensors on factory floor collecting data.
helps reduce equipment downtime
automation and machine learning,, forth industrial revolution
increases responsiveness and efficiencies to customers
replacing manual inspection and ai reduces manufacturing errors and saves money + time
connectivity and advanced engineering
industry 4.0 brings disruptive tech like VR, robotics and automation
outsourcing meaning
getting goods or services from an outside provider
- CRO CMO CDMO
- normally in countries with lower wages
- outside provider may have specific specialisms (synthesis, assays, formulation, manufacturing apis)
- also virtual pharma companies (outsource research and development)
collabsssss
- big pharma + pre competitive collaboration (to share costs for technology development)
- with small // biotech companies (which provide specialised expertise in technology or disease areas) basically provide the pharma company with their expertise
- partnering with academia //non profits (to access basic research)
in licensing
when a company receives the rights to a product or technology or ip from another company
- right to develop a compound
- right to use a technology
pay for legal rights from external organisations
allows them to avoid risk (early stage work is done by another company!!)
acquisition
- take overs and merges
- consolidate duplicated operations to reduce costs
- restock pipeline
divestment out licensing
dispose none core assets or product for others to use.
(generics, OTC drugs,, consumer goods)
- licence out compounds that are not going to be developed in house (for new disease areas)
new modalities
new types of molecule, mode of action or novel targets
- biologics
- undruggable targets ( protein protein interactions
- gene therapy
- rna
personalised medicine
in well defined patient populations
- bio markers for disease and adverse drug reactions
- treatments targeted to patients
- improves efficacy and safety
requires a greater level of patient involvement in earlier drug development
other industry changes
repositioning
new business and financial models
repositioning
applying for an existing compound for a different disease
new business and financial models
for rare diseases and antibiotics
to couple drugs with devices,, software,, and diagnostics
